4 RNA Therapeutics Stocks Leading the Next Wave of InnovationZacks Investment Research · Sep 28, 2026
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy PlatformMarketBeat · Sep 24, 2026
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform TranscriptSeeking Alpha · Sep 24, 2026
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery PlatformBusiness Wire · Sep 23, 2026
Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency ProgramSeeking Alpha · Sep 21, 2026
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics PlatformGuruFocus · Sep 18, 2026Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.00 | -$0.84 | Beat |
| May 7, 2026 | -$1.03 | -$0.95 | Beat |
| Mar 3, 2026 | -$0.92 | -$1.03 | Miss |
| Nov 10, 2025 | -$0.80 | -$0.49 | Beat |
| Aug 11, 2025 | -$0.89 | -$0.34 | Beat |
| May 12, 2025 | -$1.58 | -$0.52 | Beat |